|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Mexiletine#Adult Indications and Dosage]] |
| {{Mexiletine}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Dosage and Administration==
| |
| | |
| The dosage of mexiletine hydrochloride must be individualized on the basis of response and tolerance, both of which are dose-related. Administration with food or antacid is recommended. Initiate mexiletine therapy with 200 mg every eight hours when rapid control of arrhythmia is not essential. A minimum of two to three days between dose adjustments is recommended. Dose may be adjusted in 50 or 100 mg increments up or down.
| |
| | |
| As with any antiarrhythmic drug, clinical and electrocardiographic evaluation (including Holter monitoring if necessary for evaluation) are needed to determine whether the desired antiarrhythmic effect has been obtained and to guide titration and dose adjustment.
| |
| | |
| Satisfactory control can be achieved in most patients by 200 to 300 mg given every eight hours with food or antacid. If satisfactory response has not been achieved at 300 mg q8h, and the patient tolerates mexiletine well, a dose of 400 mg q8h may be tried. As the severity of CNS side effects increases with total daily dose, the dose should not exceed 1200 mg/day.
| |
| | |
| In general, patients with [[renal failure]] will require the usual doses of mexiletine hydrochloride. Patients with severe liver disease, however, may require lower doses and must be monitored closely. Similarly, marked right-sided congestive heart failure can reduce hepatic metabolism and reduce the needed dose. Plasma level may also be affected by certain concomitant drugs (see PRECAUTIONS, Drug Interactions).
| |
| | |
| <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MEXILETINE HYDROCHLORIDE CAPSULE [TEVA PHARMACEUTICALS USA INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=693da40b-26d4-40d6-87d1-158e256f40ab | publisher = | date = | accessdate = 3 March 2014 }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{Antiarrhythmic agents}}
| |
| | |
| [[Category:Sodium channel blockers]]
| |
| [[Category:Phenol ethers]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |